Stoke Therapeutics Inc. (STOK)
NASDAQ
33.09
-0.37 (-1.09%)
Closed
Aug 26, 2026
Day's Range
32.6033.52
52 wk Range
18.0040.22
Financial Statements - STOK - Stoke Therapeutics Inc.
Revenue
184.42M▲ 404.5%
Net Income
-6.88M▲ 92.3%Net Margin -3.7%
EBITDA
-18.82M▲ 81.0%
Free Cash Flow
44.91M▲ 151.6%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 184.42M | 36.55M | 8.78M | 12.40M | 0 | 0 |
| Cost of Goods | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -20.59M | -101.37M | -114.77M | -104.35M | -86.06M | -53.04M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -51K | -247K | 166K | 167K | 140K | 101K |
| Pre Tax Income | -6.88M | -88.98M | -104.69M | -101.06M | -85.80M | -52.24M |
| Income Tax | - | - | - | - | - | - |
| Net Income | -6.88M | -88.98M | -104.69M | -101.06M | -85.80M | -52.24M |
| EPS Basic | -0.12 | -1.65 | -2.38 | -2.6 | -2.34 | -1.56 |
| EPS Diluted | -0.12 | -1.65 | -2.38 | -2.6 | -2.34 | -1.56 |
| Basic Shares Outstanding | 59.21M | 54M | 43.99M | 38.89M | 36.73M | 33.48M |
| Diluted Shares Outstanding | 59.21M | 54M | 43.99M | 38.89M | 36.73M | 33.48M |
| Ebit | -20.59M | -101.37M | -114.77M | -104.35M | -86.06M | -53.04M |
| Ebitda | -18.82M | -99.19M | -112.30M | -102.81M | -85.09M | -52.15M |
| Net Income Continuous Operations | -6.88M | -88.98M | -104.69M | -101.06M | -85.80M | -52.24M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
